Suk Gu Lee
Sungkyunkwan University · Medicine
About the Lab
Professor Suk Gu Lee's research lab specializes in liver transplantation and hepatocyte-based therapies, with a focus on improving outcomes in pediatric and adult liver disease. The lab investigates innovative approaches such as hepatocyte transplantation for glycogen storage disease, bioartificial liver systems using porcine hepatocyte spheroids, and the safe utilization of hepatitis B core antibody-positive donor grafts. Key research directions include reducing biliary complications in living donor liver transplantation through advanced surgical techniques like high hilar dissection, and understanding long-term allograft fibrosis in pediatric transplant recipients. The lab also explores strategies to expand the donor organ pool while maintaining patient safety through effective antiviral prophylaxis.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15Glycogen storage disease type I (GSD-I) is a group of autosomal recessive disorders with an incidence of 1 in 100,000. The two major subtypes are GSD-Ia, caused by a deficiency of glucose-6-phosphatase (G6Pase), and GSD-Ib, caused by a deficiency of glucose-6-phosphate transporter (G6PT). We report that a substantial improvement was achieved following several infusions of hepatocytes in a patient with GSD-Ib. Hepatocytes were isolated from the unused cadaveric whole livers of two donors. At the
Biliary complications after living donor liver transplantation (LDLT) continue to be problematic. For reducing the biliary complications, the authors applied an intrahepatic Glissonian approach to the recipient hepatectomy. We called this Glissonian dissection technique at the high hilar level high hilar dissection (HHD). In this study, we introduced this HHD technique and evaluated its outcome in 31 recipients of a living donor liver transplant (LDLT). With total occlusion of hepatoduodenal lig
In conclusion, LDLT showed poorer outcome than DDLT. This should be considered to select optimal strategy for HCC.
This study analyzed factors related to allograft fibrosis in clinically stable pediatric liver transplantation patients. Pediatric patients who underwent liver transplantation from January 1997 to January 2008 and further underwent 10-year protocol biopsies were examined. Grades of inflammation and fibrosis were classified based on Banff criteria and the Liver Allograft Scoring (LAF) system, respectively. Risk factors for fibrosis were analyzed using logistic regression. Sixty-six patients with
Bioartificial livers (BAL) may offer acute liver failure (ALF) patients an opportunity for cure without liver transplantation. We evaluated the efficacy of a spheroid-based BAL system, containing aggregates of porcine hepatocytes, in a porcine model of ALF. ALF pigs were divided into three groups. The control group consisted of treatment naïve pigs (n = 5), blank group consisted of pigs that were attached to the BAL system not containing hepatocytes for 12 hours (n = 5) and BAL group consisted o
The use of hepatitis B core antibody-positive (HBcAb+) grafts for liver transplantation (LT) has the potential to safely expand the donor pool, as long as proper prophylaxis against de novo hepatitis B (DNHB) is employed. The aim of this study was to characterize the longterm outcome of pediatric LT recipients of HBcAb + liver grafts under a prophylaxis regimen against DNHB using hepatitis B virus (HBV) vaccine and hepatitis B immunoglobulin (HBIG). From June 1996 to February 2013, 49 patients r
Research Areas
Dive deeper into Suk Gu Lee's research on Nubint
Open this lab's papers in the app to read with AI, summarize, and cite in your writing.